Key result
Novel human iPSC line successfully models pembrolizumab-induced myocarditis and type 1 diabetes.
Why the study?
Immune checkpoint inhibitor-induced myocarditis is a severe immune-related adverse event with heterogeneous clinical presentations and potential genetic susceptibility, making an expanded repertoire of induced pluripotent stem cell lines critical for investigating its heterogeneity and underlying mechanisms.
This newly generated iPSC line from a patient with pembrolizumab-induced myocarditis and concurrent type 1 diabetes provides a preclinical cellular model to investigate the heterogeneity and underlying mechanisms of immune checkpoint inhibitor-induced myocarditis.
Immune checkpoint inhibitor-induced myocarditis (ICIM) is a severe immune-related adverse event with heterogeneous clinical presentations and potential genetic susceptibility. Here, we established a human induced pluripotent stem cell (iPSC) line from an ICIM patient who developed concurrent type 1 diabetes following ICI treatment with Pembrolizumab. This line exhibited typical morphology, normal female karyotype, pluripotency, trilineage differentiation into three germ layers, Sendai virus clearance, and no mycoplasma contamination. Given the fulminant nature and diverse clinical presentations of ICIM, expanding the repertoire of iPSC lines is critical for investigating ICIM heterogeneity and its underlying mechanisms.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2026) studied Immune checkpoint inhibitor-induced myocarditis and concurrent type 1 diabetes (n=1). Pembrolizumab was evaluated on Generation and characterization of human induced pluripotent stem cell line SCVli192-A. Human iPSC line SCVli192-A from 1 female patient with pembrolizumab-induced myocarditis and type 1 diabetes showed normal karyotype, pluripotency, and differentiation into 3 germ layers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: